Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a 1-for-6.25 share consolidation (reverse stock split) of its common shares, following shareholder approval of a special resolution. The consolidation will result in 1,022,177 common shares issued and outstanding, with no fractional shares issued. Trading on a post-consolidated basis is expected to begin on January 20, 2026, under the symbol “PBM” on the Nasdaq Capital Market. Continental Stock Transfer & Trust Company is the exchange agent for the consolidation, with beneficial holders encouraged to contact their broker for more information.

Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, the first to be listed on Nasdaq. The company is dedicated to developing nature-derived psychedelic medicine for mental health needs, focusing on an evidence-based approach for safe and effective treatments. The share consolidation aims to streamline operations and maintain compliance with Nasdaq listing standards, with potential risks and uncertainties outlined in regulatory filings. The company emphasizes the importance of clinical research and regulatory approval for its product candidates to ensure safety and efficacy.

Read more at GlobeNewswire: Psyence BioMed Announces Effective Date for 1-for-6.25